American Medical Systems Announces European Launch of Conceal® Low Profile Reservoir
MINNETONKA, Minnesota and BREUKELEN, Netherlands, November 11, 2011 /PRNewswire/ --
American Medical Systems (AMS), a leading provider of world-class devices and therapies for male and female pelvic health, today announced the European launch of its new Conceal® Low Profile Reservoir, an enhancement to the already market-leading AMS 700® three-piece inflatable penile prosthesis for the treatment of erectile dysfunction (ED). To mark this launch, Dr. Koenraad Van Renterghem, Jessa Hospital in Hasselt, Belgium, and Dr. Enrique Lledo, Gregorio Maranon Hospital in Madrid, Spain, each implanted an AMS 700 three-piece inflatable penile prosthesis with the new Conceal Low Profile Reservoir on Sept. 15, 2011.
"With this new reservoir design, AMS continues to demonstrate our commitment to prosthetic urology and support to our physicians," said Whitney Erickson, senior vice president and general manager for Men's Health at AMS. "As a company, we remain dedicated to raising the bar for innovation in the treatment of erectile dysfunction, and our customers can rest assured that we will continue to invest in new technology to improve the treatment options for physicians and the quality of life for their patients."
The Conceal reservoir is compatible with all AMS 700 cylinder and pump configurations and offers the flexibility of a one-size-fits-all design that can accommodate 65 - 100ml of fluid, based on the specific needs of each patient. The low-profile design features the same functionality and reliability as the current spherical reservoir, and Conceal is available with or without AMS' InhibiZone® antibiotic treatment.
AMS' penile prosthetic solutions provide a permanent, surgical option for men who are unsatisfied with the results from other ED treatment options, such as oral medications, and have a greater than 90 percent patient satisfaction rate.
About American Medical Systems
American Medical Systems, headquartered in Minnetonka, Minnesota, is a diversified supplier of medical devices and procedures to treat incontinence, erectile dysfunction, benign prostatic hyperplasia (BPH), pelvic floor prolapse and other pelvic disorders in men and women. These disorders can significantly diminish one's quality of life and profoundly affect social relationships. In recent years, the number of people seeking treatment has increased markedly as a result of longer lives, higher-quality-of-life expectations and greater awareness of new treatment alternatives. American Medical Systems' products reduce or eliminate the incapacitating effects of these diseases, often through minimally invasive therapies. The Company's products were used to treat approximately 340,000 patients in 2010. AMS is a wholly owned subsidiary of Endo Pharmaceuticals (Nasdaq: ENDP), a U.S.-based, specialty healthcare solutions company, focused on high-value branded products, services and devices and specialty generics (http://www.endo.com).
More information about the Company and its products can be found at its website http://www.AmericanMedicalSystems.com and in the Company's Annual Report on Form 10-K for 2010 and its other SEC filings.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in our Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Share this article